An inhibitory effect of tumor necrosis factor-alpha antagonist to gene expression in monocrotalineinduced pulmonary hypertensive rats model

Korean Journal of Pediatrics

Volumn 56, Issue 3, 2013, Pages 116-124

  Kwon, Jung Hyun ^a   Kim, Kwan Chang ^a   Cho, Min Sun ^a   Kim, Hae Soon ^a   Sohn, Sejung ^a   Hong, Young Mi ^a  

^a Ewha Womans University School of Medicine   (South Korea)

Author keywords

Gene expression; Infliximab; Monocrotaline; Pulmonary hypertension

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; INFLIXIMAB; MATRIX METALLOPROTEINASE; MONOCROTALINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HEART RIGHT VENTRICLE PRESSURE; HEART WEIGHT; HEMODYNAMIC PARAMETERS; HISTOLOGY; MALE; MICROARRAY ANALYSIS; NONHUMAN; PULMONARY HYPERTENSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84875181979     PISSN: 17381061     EISSN: 20927258     Source Type: Journal    
DOI: 10.3345/kjp.2013.56.3.116     Document Type: Article

References (32)

1. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004;109:159-165.
2. McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, et al. Gene therapy targeting survivin selectively induces pul monary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 2005;115:1479-1491.
3. Dorfmüller P, Perros F, Balabanian K, Humbert M. Infammation in pulmonary arterial hypertension. Eur Respir J 2003;22:358-363.
4. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):13S-24S.
5. Sakao S, Taraseviciene-Stewart L, Lee JD, Wood K, Cool CD, Voelkel NF. Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J 2005;19:1178-1180.
6. Jankov RP, Kantores C, Belcastro R, Yi M, Tanswell AK. Endothelin-1 inhibits apoptosis of pulmonary arterial smooth muscle in the neonatal rat. Pediatr Res 2006;60:245-251.
7. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT; AntiTNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factoralpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-3140.
8. Baughman RP. Pulmonary hypertension associated with sarcoidosis. Arthritis Res Ther 2007;9 Suppl 2:S8.
9. Miyauchi T, Yorikane R, Sakai S, Sakurai T, Okada M, Nishikibe M, et al. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res 1993;73:887-897.
10. Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med 2000;6:698-702.
11. Ono S, Voelkel NF. PAF antagonists inhibit monocrotaline-induced lung injury and pulmonary hypertension. J Appl Physiol 1991;71: 2483-2492.
12. Prié S, Leung TK, Cernacek P, Ryan JW, Dupuis J. The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin2-yloxy)-3-methoxy-3,3-diphe nyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats. J Pharmacol Exp Ther 1997;282:1312-1318.
13. Sakuma F, Miyata M, Kasukawa R. Suppressive effect of prostag landin E1 on pulmonary hypertension induced by monocrotaline in rats. Lung 1999;177:77-88.
14. Lim KA, Shim JY, Cho SH, Kim KC, Han JJ, Hong YM. Effect of endothelin receptor blockade on monocrotaline-induced pulmonary hypertension in rats. Korean J Pediatr 2009;52:689-695.
15. Lim KA, Kim KC, Cho MS, Lee BE, Kim HS, Hong YM. Gene expression of endothelin-1 and endothelin receptor a on monocrotaline-induced pulmonary hypertension in rats after bosentan treatment. Korean Circ J 2010;40:459-464.
16. Koo HS, Kim KC, Hong YM. Gene expressions of nitric oxide synthase and matrix metalloproteinase-2 in monocrotaline-induced pulmonary hypertension in rats after bosentan treatment. Korean Circ J 2011;41:83-90.
17. Itoh T, Nagaya N, Fujii T, Iwase T, Nakanishi N, Hamada K, et al. A combination of oral sildenafl and beraprost ameliorates pulmo nary hypertension in rats. Am J Respir Crit Care Med 2004;169:34-38.
18. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, Ermert L, et al. Chronic sildenafl treatment inhibits monocrotalineinduced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004;169:39-45.
19. Booth AD, Jayne DR, Kharbanda RK, McEniery CM, Mackenzie IS, Brown J, et al. Infiximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 2004;109:1718-1723.
20. Xiong W, MacTaggart J, Knispel R, Worth J, Persidsky Y, Baxter BT. Blocking TNF-alpha attenuates aneurysm formation in a murine model. J Immunol 2009;183:2741-2746.
21. Bradham WS, Bozkurt B, Gunasinghe H, Mann D, Spinale FG. Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc Res 2002;53:822-830.
22. Bargagli E, Galeazzi M, Bellisai F, Volterrani L, Rottoli P. Infiximab treatment in a patient with systemic sclerosis associated with lung fbrosis and pulmonary hypertension. Respiration 2008;75:346-349.
23. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fbrosis. J Rheumatol 1997; 24:663-665.
24. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002;50:206-211.
25. Grundmann S, Hoefer I, Ulusans S, van Royen N, Schirmer SH, Ozaki CK, et al. Anti-tumor necrosis factor-{alpha} therapies attenuate adaptive arteriogenesis in the rabbit. Am J Physiol Heart Circ Physiol 2005;289:H1497-H1505.
26. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 2000;14:2123-2133.
27. Roten L, Nemoto S, Simsic J, Coker ML, Rao V, Baicu S, et al. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. J Mol Cell Cardiol 2000;32:109-120.
28. Kulik TJ. Pathophysiology of acute pulmonary vasoconstriction. Pediatr Crit Care Med 2010;11(2 Suppl):S10-S14.
29. Jankov RP, Luo X, Belcastro R, Copland I, Frndova H, Lye SJ, et al. Gadolinium chloride inhibits pulmonary macrophage influx and prevents O(2)-induced pulmonary hypertension in the neonatal rat. Pediatr Res 2001;50:172-183.
30. Hoehn T, Stiller B, McPhaden AR, Wadsworth RM. Nitric oxide synthases in infants and children with pulmonary hypertension and congenital heart disease. Respir Res 2009;10:110.
31. Lee YH, Kim KC, Cho MS, Hong YM. Changes of pulmonary pathology and gene expressions after simvastatin treatment in the monocrotaline-induced pulmonary hypertension rat model. Korean Circ J 2011;41:518-527.
32. Sutendra G, Dromparis P, Bonnet S, Haromy A, McMurtry MS, Bleackley RC, et al. Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFα contributes to the pathogenesis of pulmonary arterial hypertension. J Mol Med (Berl) 2011;89:771-783.